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Abstract 
Objective 
To evaluate the reduction in thrombotic events (TE) in patients with essential 
thrombocythaemia (ET) treated with anagrelide versus hydroxyurea + aspirin (HU + ASA). 
Methods 
A questionnaire was developed using 2008 WHO diagnostic criteria, and thrombotic risk 
factors were stratified according to Landolfi criteria. Through questionnaire completion, 
clinicians at Hungarian haematological centres entered data into the Hungarian MPN Registry 
on patients with myeloproliferative neoplasms. Based on ET registry data, TEs in 
anagrelide‐treated patients (n = 139) were compared with HU + ASA‐treated patients (n = 
141).  
Results 
Patients were followed up for (median) 6 yr. TEs were reported in significantly fewer 
anagrelide‐treated patients versus HU + ASA (15.1% versus 49.6%; P < 0.001). Numbers of 
major arterial and major venous events were similar between the groups, although there were 
over fivefold more minor arterial and minor venous events in the HU + ASA group (P < 
0.001). While median age at diagnosis was older and length of follow‐up shorter in the HU + 
ASA group (P < 0.05), this did not influence TE incidence; medication and TE before 
diagnosis only influenced TE incidence.  
Conclusions 
Anagrelide significantly decreased the number of patients experiencing minor arterial and 
minor venous TEs versus HU + ASA over 6 yr. Risk of TE after diagnosis was significantly 
increased if the patient had TE before diagnosis.  
The myeloproliferative neoplasms (MPN), polycythaemia vera (PV), essential 
thrombocythaemia (ET) and primary myelofibrosis (PMF) are characterised by stem 
cell‐derived clonal myeloproliferation 1, 2. Most patients with PV, ET and PMF possess a 
Janus kinase 2 (JAK2; 9p24) mutation, with approximately 96%, 55% and 65% displaying 
activating mutations in JAK2V617F, respectively 3-5.  
In PV and ET, survival or leukaemic transformation does not seem to be affected by the 
presence or allele burden of JAK2V617F 5-7 but, in ET, the presence of JAK2V617F has been 
associated with an increased risk of arterial thrombosis 7, 8. As such, the focus of risk 
stratification in PV and ET is the likelihood of thrombotic complications 9. An international 
study examining thrombotic risk factors in 891 patients with ET found that 109 (12%) 
patients experienced arterial (n = 79) or venous (n = 37) thrombosis. Predictors of arterial 
thrombosis included an age of more than 60 yr, history of thrombosis, cardiovascular risk 
factors, leukocytosis (>11 × 109/L) and presence of JAK2V617F; male gender only predicted 
venous thrombosis 8.  
Survival rates are high in both ET and PV (80% at 15 yr and 75% at 10 yr, respectively) 7, 10, 
although the risk of thrombosis is >20% in both disorders 11. Consequently, as with risk 
stratification, the focus of current PV and ET management is primarily to prevent 
thrombo‐haemorrhagic complications without increasing the risk of bleeding, but also to 
control symptoms 9.  
The Hungarian MPN Working Group (HUMYPRON GROUP) was established to examine 
the heterogeneity of therapeutic management of MPN in Hungary. To enable this, in 2013, the 
HUMYPRON GROUP created an MPN Registry 12. The MPN registry has three main areas 
of interest: to collect epidemiological, diagnostic, and therapeutic data, and follow‐up 
complications and disease transformations; to investigate adherence to the WHO 2008 
diagnostic criteria 1 and Landolfi therapeutic guidelines 13 to gain insight into vascular and 
haematological complications; and to identify important issues and gaps in management, and 
promote internationally accepted standard of care 14.  
The MPN registry has been approved and authorised by the Hungarian authorities 
Egészségügyi Tudományos Tanács‐Tudományos és Kutatásetikai Bizottsága (ETT‐TUKEB) 
12. Its computer software allows for continuing update. Data on patients with PV, ET and 
idiopathic myelofibrosis (IMF) are entered online into the registry. All registered 
haematologists entering data are permitted to initiate search and association analysis.  
Controlled studies comparing anagrelide with hydroxyurea have demonstrated conflicting 
results with regard to protection against thrombosis 15, 16. Herein, based on MPN registry 
data, the outcomes of ET patients treated with anagrelide were compared with ET patients 
treated with hydroxyurea + aspirin. Specifically, the effects of treatment on thrombotic events 
(TEs) are reported.  
Patients and methods 
Patients and data collection 
Data on classical MPN patients were collected electronically using an easily evaluable 
questionnaire, developed through close cooperation between experts in haematology and 
information technology. The questionnaire was developed in line with the 2008 revision of 
the World Health Organization (WHO) diagnostic criteria 1, with focus on complications, risk 
stratification and treatment. Thrombotic risk and the risk‐adapted treatment characteristics 
were stratified according to the Landolfi criteria 13. Accordingly, a score (range 0–3.5) is 
allocated to each risk factor present: age (<40; 40–55; 56–65; >65 yr), hypertension, 
dyslipidaemia, platelet count (>1000 × 109/L), leucocyte count (12 × 109/L), smoking, 
diabetes and past history of thrombosis.  
Through questionnaire completion, clinicians at major and smaller haematological centres in 
Hungary entered data into the Hungarian MPN Registry on all patients with PV, ET and IMF 
who they had diagnosed using WHO criteria and treated. Based on registry data, the 
characteristics and outcomes of ET patients treated with anagrelide or with hydroxyurea + 
aspirin were extracted.  
Definition of thrombotic events 
Minor and major arterial and venous TEs were classified according to the following 16:  
1. Major arterial thrombosis, including stroke, myocardial infarction, peripheral arterial 
disease and other arterial thrombosis;  
2. Minor arterial events, including transient ischaemic attack (TIA), angina pectoris, 
unstable angina, generalised convulsions, erythromelalgia, ocular symptoms, other 
peripheral arterial microcirculatory disturbances and other minor arterial events;  
3. Major venous thrombosis, including iliofemoral thrombosis, pulmonary embolism, 
splanchnic vein thrombosis and other major venous events;  
4. Minor venous events, including superficial thrombophlebitis, and other minor venous 
events.  
Statistical analysis 
Metric variables were compared between subgroups either by t‐test for independent samples 
or by a parametric analysis of variance (anova; including post hoc tests by Hochberg's GT2 
method). Comparisons of dichotomous variables were performed either by Fisher's exact test 
or by exact chi‐square test (with provision of adjusted residuals). Logistic regression analysis 
was used to investigate the influence of the following covariates on TE occurrence: 
medication (anagrelide vs. hydroxyurea + aspirin), length of follow‐up, Landolfi risk 
summary score, age at diagnosis (in years or <60 yr vs. ≥60 yr), gender (male vs. female), 
JAK2‐positive status (no vs. yes) and TE prior to diagnosis (no vs. yes). Type I error was not 
adjusted for multiple testing, and therefore, the results of inferential statistics are descriptive 
only. Statistical analysis was performed using the open‐source R statistical software package, 
version 3.1.2 (The R Foundation for Statistical Computing, Vienna, Austria), and statistical 
tests were interpreted at a 5% significance level.  
Study approval 
The study was approved by the ETT‐TUKEB and was performed in compliance with the 
Declaration of Helsinki. Patient consent was not obtained, but the data are presented on a 
group basis and there is no risk of patient identification.  
Results 
Database and extraction 
During the first year of Registry data collection, 15 major or smaller haematological centres 
provided patient data, yielding 350 evaluable patients with ET. Of these, 139 patients with ET 
were treated with anagrelide and 141 were treated with hydroxyurea + aspirin. Patients were 
followed up for a median of 6 yr (Table 1).  
Table 1. Characteristics of patients with ET treated with anagrelide vs. hydroxyurea + aspirin  
 
Anagrelide 
Hydroxyurea + 
aspirin 
Total 
P value  
N = 139  N = 141  N = 280  
Gender 
Male, n (%)  41 (29.5) 48 (34.0) 89 (31.8) 
0.443 
Female, n (%)  98 (70.5) 93 (66.0) 191 (68.2) 
Age at diagnosis, yr, median 59.8 64.3 61.9 
0.004 (minimum–maximum) (25.1–91.1) (28.9–89.3) 
(25.1–
91.1) 
Mean ± standard deviation 58.1 ± 14.4 62.6 ± 11.1 60.4 ± 13.0 
Age at diagnosis categorised, yr 
<60 yr, n (%)  71 (51.1) 57 (40.4) 128 (45.7) 
0.093 
≥60 yr, n (%)  68 (48.9) 84 (59.6) 152 (54.3) 
JAK2 positive, yes, n (%)  79 (57.2)a 94 (66.7) 173 (62.0) 0.111a 
Length of follow‐up, yr, median 7 5 6 
0.035 (minimum–maximum) (0–25) (0–25) (0–25) 
Mean ± standard deviation 8.0 ± 5.5 6.6 ± 5.3 7.3 ± 5.5 
Landolfi risk summary score, 
median 
4.5 4.5 4.5 
0.790 
(minimum–maximum) (2.0–10.5) (1.5–10.0) (1.5–10.5) 
Mean ± standard deviation 5.1 (1.7) 5.1 (1.8) 5.1 (1.7) 
TE prior to diagnosis, yes, n (%)  24 (17.3) 31 (22.0) 55 (19.6) 0.368 
TE after diagnosis, yes, n (%)  
Total 21 (15.1) 70 (49.6) 91 (32.5) <0.001a 
Arterial minor 6 (4.3) 31 (22.1)b 37 (13.3) <0.001a 
Arterial major 2 (1.4) 3 (2.1) 5 (1.8) 0.999a 
Venous minor 5 (3.6) 30 (21.3) 35 (12.5) <0.001a 
Venous major 12 (8.6) 8 (5.7) 20 (7.1) 0.363a 
Bleeding event, yes, n (%)  4 (2.9) 2 (1.4) 6 (2.1) 0.446b 
 ET, essential thrombocythaemia; TE, thromboembolic event.  
 a Compared with patients categorised as ‘no, n (%)’.  
 b Missing data for one patient.  
Patient characteristics and thrombotic risk 
In both groups, the male‐to‐female ratio was approximately 1 : 2, and most patients were 
JAK2 V617F‐positive (Table 1). The Landolfi risk summary score was median 4.5 (total 
range 1.5–10.5) for both the anagrelide and hydroxyurea + aspirin groups. There was no 
significant between‐group difference in gender, age at diagnosis categorised (<60 and ≥60 yr), 
JAK2V617F positivity (yes vs. no) or Landolfi risk summary score.  
Prior to diagnosis, TEs were reported in similar numbers of patients in each group (Table 1). 
After diagnosis, TEs were reported in 15.1% of patients in the anagrelide group and 49.6% of 
patients in the hydroxyurea + aspirin group (P < 0.001; Table 1). The numbers of major 
arterial and major venous events were similar between the groups. However, there were more 
than fivefold between‐group differences in both minor arterial and minor venous events (both 
P < 0.001), which were more frequently reported in the hydroxyurea + aspirin group (Table 
1). There were four haemorrhagic complications in the anagrelide group and two in the 
hydroxyurea + aspirin group, although the difference was not significant. Arterial and venous 
TEs according to treatment group and gender, and treatment group and <60 yr/≥60 yr are 
shown in Table 2.  
Table 2. TEs occurring after diagnosis according to gender and age group of patients with ET  
 
Anagrelide Hydroxyurea + aspirin 
P valuea 
N = 139  N = 141  
Gender Male Female Male Female 
 
 
n = 41  n = 98  n = 48  n = 93  
TE after diagnosis, yes, n (%)  
Total 5 (12.2)b 16 (16.3)b 24 (50.0)c 46 (49.5)c <0.001 
Arterial minor 2 (4.9) 4 (4.1)b 13 (27.1)c 18 (19.6)d <0.001 
Arterial major 1 (2.4) 1 (1.0) 1 (2.1) 2 (2.2) 0.94 
Venous minor 1 (2.4) 4 (4.1)b 7 (14.6) 23 (24.7)c <0.001 
Venous major 1 (2.4) 11 (11.2) 5 (10.4) 3 (3.2) 0.075 
Bleeding event 1 (2.4) 3 (3.1) 1 (2.1) 1 (1.1) 0.94 
Age group <60 yr ≥60 yr <60 yr ≥60 yr 
 
 
n = 71  n = 68  n = 57  n = 84  
TE after diagnosis, yes, n (%)  
Total 10 (14.1) 11 (16.2)b 28 (49.1)c 42 (50.0)c <0.001 
Arterial minor 5 (7.0)b 1 (1.5)b 11 (19.6)d 20 (23.8)c <0.001 
Arterial major 0 (0) 2 (2.9) 2 (3.5) 1 (1.2) 0.40 
Venous minor 2 (2.8)b 3 (4.4) 11 (19.3) 19 (22.6)c <0.001 
Venous major 5 (7.0) 7 (10.3) 5 (8.8) 3 (3.6) 0.42 
Bleeding event 2 (2.8) 2 (2.9) 1 (1.8) 1 (1.2) 0.90 
 ET, essential thrombocythaemia; TE, thromboembolic event.  
 a Chi‐square comparison of categorical variables between anagrelide/male vs. 
anagrelide/female vs. hydroxyurea + aspirin/male vs. hydroxyurea + aspirin/female; 
and between anagrelide/<60 vs. anagrelide/≥60 vs. hydroxyurea + aspirin/<60 vs. 
hydroxyurea + aspirin/≥60.  
 b Lower than expected (P < 0.05).  
 c Higher than expected (P < 0.05).  
 d Missing data for one patient.  
There was a significant between‐group difference in the continuous variables, median age at 
diagnosis (older in the hydroxyurea + aspirin group) and length of follow‐up (shorter in the 
hydroxyurea + aspirin group) (Table 1). Regression analysis indicated that these findings did 
not influence the incidence of TE; medication, Landolfi risk summary score and TE prior to 
diagnosis only were found to influence the incidence of TE (Table 3).  
Table 3. Influence of ET cohort characteristics on the occurrence of TE  
Variables 
P 
value  
Exp(B): odds 
ratio 
EXP(B): 95% 
CI 
Medication (anagrelide vs. hydroxyurea + 
aspirin) 
<0.001 8.551 4.250, 17.207 
Gender (male vs. female) 0.447 1.297 0.663, 2.537 
Age at diagnosis categorised (<60 yr vs. ≥60 
yr) 
0.218 0.638 0.311, 1.305 
JAK2 positive (no vs. yes)  0.538 1.227 0.640, 2.353 
Length of follow‐up (yr) 0.750 1.010 0.951, 1.072 
Landolfi risk summary score <0.001 1.582 1.235, 2.027 
TE prior to diagnosis (no vs. yes) 0.016 3.195 1.247, 8.188 
 ET, essential thrombocythaemia; TE, thromboembolic event.  
 Logistic regression with categorical age (included cases, n = 279); the dependent 
variable is the number of patients with a TE after diagnosis (‘yes’).  
Discussion 
In this evaluation of data on ET patients in the Hungarian MPN Registry, treatment with 
anagrelide significantly decreased the number of patients experiencing minor arterial and 
minor venous TEs compared with hydroxyurea + aspirin over a median of 6 yr. In this ET 
patient cohort, risk of TE after diagnosis was significantly increased by Landolfi risk 
summary score and if the patient had experienced a TE prior to diagnosis. No other risk factor 
for TE was identified. Anagrelide has demonstrated efficacy in reducing platelet counts in 
patients with ET and thrombocytosis due to myeloproliferative disorders, and control of 
platelet counts is reported to reduce the incidence of TEs in ET 17.  
Our findings are contradictory to previous studies comparing hydroxyurea with anagrelide, 
which have also demonstrated conflicting results 15, 16. A randomised trial of 809 with ET 
(Polycythemia Vera Study Group diagnostic criteria) who were at high risk for vascular 
events showed hydroxyurea + low‐dose aspirin was superior to anagrelide + low‐dose aspirin 
in reducing the risk of arterial thrombosis and serious haemorrhage, after a median follow‐up 
of 39 months 15. A decreased rate of venous thromboembolism was observed in the 
anagrelide group, although patients were more likely to discontinue treatment due to adverse 
events. Another comparative study in 259 previously untreated, high‐risk patients with ET 
(WHO diagnostic criteria) found that there was no significant difference between the 
hydroxyurea and anagrelide groups at 6, 12 and 36 months regarding the frequency of 
ET‐related major and minor thrombo‐haemorrhagic events 16. A meta‐analysis of these trials 
reported that hydroxyurea and anagrelide were equally effective for protection against TEs 
but that there were fewer major bleeding events with hydroxyurea 18. Notably, our study had 
a longer follow‐up period (median of 72 months) than either of these studies, suggesting that 
there may be an increase in TEs in ET patients treated with hydroxyurea over time.  
While the reduction in venous thromboembolism by anagrelide compared to hydroxyurea 
appears to be consistent between previous studies 15, 16 and in this study, there is a 
discrepancy between our findings and those reported by Harrison et al. 15 regarding arterial 
events. Harrison et al. 15 observed arterial complications in 9.1% of patients in the anagrelide 
+ aspirin group versus 4.2% in the hydroxyurea + aspirin group, whereas this study there were 
5.7% versus 24.1% in the anagrelide and the hydroxyurea + aspirin groups, respectively. 
Notably, the majority of arterial thromboses prevented by hydroxyurea + aspirin were TIAs 
the former study. In contrast, we found a pronounced reduction in minor arterial 
complications (including TIAs) by anagrelide. We cannot specifically address the reason 
behind this reduction as the questionnaire used to compile Registry data grouped all minor 
events rather than detailing each event individually. However, because minor complications 
were perhaps less remarkable than major events, doctors and patients may have been less 
inclined to register them. These findings suggest a need to update this Registry questionnaire, 
to document the specific arterial and venous events experienced by patients on these 
treatments.  
Consistent with our findings, it is well established that the strongest risk factor for arterial and 
venous thrombosis is a history of these events 19. Additional risk factors for arterial 
thrombosis in ET include age >60 yr and the presence of JAK2V617F and for venous 
thrombosis is male gender 8. It is interesting to note that despite a greater number of TEs in 
patients treated with hydroxyurea + aspirin, there was no between‐group difference in the 
proportions of older patients at diagnosis or JAK2V617F‐positive patients. Notably, 
identification of JAK2V617F does not necessarily change risk stratification of patients with 
ET, but age of ≥60 yr and history of thrombosis are used to classify patients as low‐, 
intermediate‐ and high‐risk categories 9.  
To identify more clearly a patient's risk of vascular events, the Landolfi criteria can be used to 
assign a patient to a certain risk level based on a scoring system 13. Age is considered 
progressively rather than on a single threshold level, and other possible risk factors such as a 
past history of thrombosis, smoking, and high leucocyte and platelet counts are included. Our 
study showed that the Landolfi risk summary score is a significant risk factor for TE after 
diagnosis. Healthcare professionals in haematological centres in Hungary can access these 
data in <10 min giving the consulting physician rapid assessment of patient TE risk. Landolfi 
criteria have not previously been used in clinical studies and, recognising the association 
between the Landolfi summary score with TE risk after diagnosis, should be considered in 
clinical practice and in the design of future studies. Furthermore, our study highlights the 
importance of controlling those Landolfi risk factors that can be modified.  
In the present study, data on patients with ET were collected in line with WHO diagnostic 
criteria 1, and thrombotic risk and risk‐adapted treatment characteristics were stratified 
according to Landolfi criteria 13. However, as these patients were treated according to 
individual clinical practice and not in a randomised controlled trial, the influence of previous 
treatments on the risk of thrombosis cannot be ruled out. Additionally, unlike patients in the 
anagrelide group, patients receiving hydroxyurea also received aspirin. Aspirin has been 
associated with a reduction in the incidence of venous thrombosis in JAK2V617F‐positive 
low‐risk patients with ET and, in those patients with cardiovascular risk factors, the rate of 
arterial thrombosis 20. This protective effect is recognised in treatment guidelines for patients 
with ET both with and without a previous history of thrombosis 9. The contribution of aspirin 
in TE prevention could not be determined in this study in which it was used in combination 
with hydroxyurea. On the other hand, bleeding associated with aspirin may be promoted in 
ET 21, although there was no significant difference in the small numbers of bleeding 
complications in our study.  
Compared to major complications, minor arterial complications are more difficult to define, 
and their diagnosis may be more subjective. This may have led to a bias in this study because 
doctors providing the registry data were aware of the patients' treatment. This potential 
limitation of the study presents difficulties to drawing definitive conclusions that support 
treatment recommendations.  
Our finding that hydroxyurea + aspirin treatment of patients with ET significantly increased 
the risk of minor arterial and venous TEs compared with anagrelide should be considered in 
the light of current recommendations. These consider that patients with ET aged ≥60 yr with 
no thrombotic event history, and patients of any age with a history of arterial and/or venous 
TE receive hydroxyurea + aspirin 9. However, guidelines 9 advise against the use of 
anagrelide for the treatment of ET because of its previously reported association with 
increased risk of arterial thrombosis and major bleeding 9. Comparison of these two treatment 
regimens regarding the likelihood of TEs warrants further investigation among larger ET 
cohorts from real‐life clinical practice.  
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